Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life

The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer. The study revealed a number of benefits from use of topotecan in patients w...

Full description

Bibliographic Details
Main Authors: E. G. Novikova, I. A. Korneyeva, E. A. Ronina, S. A. Shcheltsyna, E. D. Pashanov
Format: Article
Language:Russian
Published: ABV-press 2014-08-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/231